ArticleBMC anesthesiology2026
Exploring the median effective dose of ciprofol for anesthesia induction in patients with heart valve disease: a prospective, single-arm, single-centre study.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The median effective dose (EDBMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimTo determine the median effective dose of ciprofol for anesthesia induction in patients undergoing cardiac valve replacement and to evaluate its safety.
methodsTwenty-seven patients with heart valve disease (HVD), aged 18–64 years with a BMI of 15–28 kg/m² and classified as American Society of Anesthesiologists (ASA) physical status II or III, were enrolled. The effective dose of ciprofol was determined using Dixon’s up-and-down method, starting from an initial dose of 0.30 mg/kg with an increment of 0.02 mg/kg. A probit model was employed to calculate the ED50 and ED95. Hemodynamic parameters, including heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO₂), and the bispectral index (BIS), were recorded at baseline and every minute for 5 min following drug administration. The incidence of adverse events, such as hypotension, bradycardia, respiratory depression, and injection pain, was also documented.
resultsThe Median Effective Dose (ED) 50 (with 95% confidence intervals, CIs) for ciprofol-induced loss of consciousness were 0.307 mg/kg (95% CI: 0.272–0.358 mg/kg) and the ED95 was 0.366 mg/kg (95% CI: 0.334–0.938 mg/kg), reflecting inherent limitations of the up-and-down method when estimating upper quantiles. Hypotension occurred in 15% of patients, and respiratory depression was observed in 26%. No patients experienced injection pain, hypoxemia, or clinically significant bradycardia.
conclusionFor anesthesia induction in patients with HVD, the ED50 and ED95 of a single intravenous dose of ciprofol were 0.307 mg/kg and 0.366 mg/kg, respectively. Ciprofol was associated with a low incidence of anesthesia-related adverse events, suggesting it is a suitable agent for anesthesia induction in patients undergoing cardiac surgery.
trial registrationhttp://www.chictr.org.cn (ChiCTR2300071427, 15/5/2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.